Olema Pharmaceuticals (OLMA) early Monday said the US Food and Drug Administration has cleared the investigational new drug application for the company's OP-3136 drug candidate to treat breast and other types of cancer.
The company is expecting to begin phase 1 testing of OP-3136 early in 2025, Olema said.
Price: 10.51, Change: +0.06, Percent Change: +0.57
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.